Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 23
SLIM LIVER: Semaglutide and HIV
SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.
SURPASS-CVOT Beyond MACE
A 2026 commentary argues that SURPASS-CVOT may require endpoints beyond MACE, but its biological framework remains a hypothesis, not new trial evidence.
Tirzepatide With Biologics in PsA
A matched 2026 study linked concurrent tirzepatide and biologic initiation with better six-month outcomes in obese psoriatic arthritis.
Emerging knee OA therapies: review map
A 2026 review maps semaglutide, local GLP-1 candidates, gene therapy and other emerging knee osteoarthritis treatments.
GLP-1 drugs and dental evidence gaps
A 2026 appraisal found promising preclinical dental findings for GLP-1 drugs, but no prospective patient study with a dental endpoint.
Low-dose tirzepatide in older adults
A 28-week Japanese cohort found high persistence and modest metabolic change with low-dose tirzepatide in selected older adults.
Obesity and knee OA: what review found
A narrative review places semaglutide evidence inside broader weight-management care for people with obesity and knee osteoarthritis.
Oral semaglutide and needle phobia
A 2026 review examines oral semaglutide for people with needle phobia, but it reports no new head-to-head trial or adherence outcome.
Peptides in three dental nerve cases
Three dental nerve-injury cases improved during a multi-agent peptide intervention, but the uncontrolled report cannot establish efficacy.
Retatrutide in a diabetic rat kidney study
A 2026 rat study found a kidney HIF-1α change with retatrutide, but no statistically confirmed protection against tissue injury.
Rural GLP-1 chart review: 40 adults
A 40-person rural chart review linked tirzepatide or semaglutide use with improved A1c and several cardiometabolic measures.
GLP-1 drugs in schizophrenia: 7 trials
Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.